ClinicalTrials.gg
RecruitingNCT06638060Updated Oct 15, 2026

Continuous Connected Patient Care (CCPC), a Pilot Testing a Novel Device for Continuous Vitals Monitoring - Older Adults Department PHC

An observational study in Aging, sponsored by Medtronic - MITG. Recruiting at 1 site in Canada. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Medtronic - MITG (part of Medtronic) · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
65 Years and older
Sex
All
01

Study summary

To confirm feasibility and accessibility of the CCPC Platform (Oxymotion, Bridge Health Solutions medication adherence software, CloudDX home kit) in two different environments - 1) hospital (Acute Care for Elderly Unit) and 2) at-home .

02

Conditions studied

  • Aging
03

In context

Lead sponsor

Medtronic - MITG is the lead sponsor of 179 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The Acute Care for Elderly Unit at SPH for 40 inpatients over the age of 65.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatients on the Acute care of the Elderly ward.

Exclusion criteria

Exclusion Criteria:

  • Lack of capacity to consent to the study including moderate-severe dementia or delirium
  • Unable to use (or does not have a caregiver who can help put on) study monitoring device at home
  • Unable to complete (or does not have a caregiver who can help complete) study questionnaires by electronic (mobile, tablet, or computer), paper, nor phone
  • Patient with known allergic reactions to any part material of the device
  • People under 40kg
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Collect patient and clinicians' feedback about the CCPC Platform

    This will be completed via an assessment of the quantitative data on how long and how often patients use this monitoring and what were the reasons that patients took the monitors on and off.

    Time frame: From enrollment to the end of follow up at 10 days

  2. Collect patient and clinicians' feedback about the CCPC Platform

    This will be completed via an assessment of the Usability Questionnaire.

    Time frame: From enrollment to the end of follow up at 10 days

  3. Collect patient and clinicians' feedback about the CCPC Platform

    This will be completed by an evaluation for potential harm, e.g. anxiety questionnaire and any patient-reported adverse events.

    Time frame: From enrollment to the end of follow up at 10 days

  4. Confirm the technical goals of the CCPC platform are met.

    This will be completed by ensuring clinician workflow is met, via feedback sessions (e.g. conversations, questionnaires).

    Time frame: From enrollment to the end of follow up at 10 days

  5. Confirm the technical goals of the CCPC platform are met.

    This will be completed via an assessment of the data flow: does the correct patient data reach the clinicians at the right time?

    Time frame: From enrollment to the end of follow up at 10 days

  6. Confirm the technical goals of the CCPC platform are met.

    This will be completed by determining if the CCPC platform provided a holistic view of each patient with vitals, medication, labs and other collected data.

    Time frame: From enrollment to the end of follow up at 10 days

07

Study locations

1 of 1 sites recruiting
  • St. Paul'sHospital
    Vancouver, British Columbia V6Z 1Y6, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Primary completion
Jun 21, 2026→Jun 21, 2027
Oct 15, 2026
Study completion
Jun 21, 2026→Jun 21, 2028
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Jun 21, 2026→Jun 21, 2027
    Study completion Jun 21, 2026→Jun 21, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06638060
Lead sponsor
Medtronic - MITG
Collaborators
Excelar, Cloud DX Inc., Bridge Health Solutions, Providence Healthcare
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Mar 13, 2025
Primary completion
Jun 21, 2027 (estimated)
Completion
Jun 21, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Elise Huisman
Contact
elise.huisman@medtronic.com
+1 236-308-4876

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion